Aperio Group’s Utah Medical Products UTMD Stock Holding History

Aperio Group’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-790	Closed	-$76K	–	2743
2019 Q2	$76K	Buy	+790	New	+$66.5K	﹤0.01%	2459

Other funds holding UTMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $67.5B AUM 28.09% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aperio Group's UTMD Position: Q3 2019 in Review

Aperio Group sold out of Utah Medical Products (UTMD) in Q3 2019, closing a stake of 790 shares — an estimated $76K sold.

Aperio Group first reported a position in UTMD in Q2 2019 and held it in 1 quarter. The position peaked at $76K in Q2 2019. 97 funds tracked by Wall St. Rank hold UTMD as of Q3 2019.

Aperio Group reported no remaining Utah Medical Products position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 790 Utah Medical Products shares in Q3 2019, an estimated $76K.
Aperio Group first reported a position in Utah Medical Products in Q2 2019 and held it in 1 quarter.
Aperio Group's Utah Medical Products position peaked at $76K in Q2 2019.
97 funds tracked by Wall St. Rank held Utah Medical Products as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.